Skip to main content

Table 1 Characteristic of the selected studies on the prevalence of Mets

From: Global prevalence of cardiometabolic risk factors in the military population: a systematic review and meta-analysis

Author, year

Country

Study type

Study year

Study population

Sampling

Sample size

Mean age/ Range

Outcome

Definition/Criteria

Prevalence%(95% CI)

Payab, 2017 [13],

Iran

C/S

2015

Military

Convenience

2200

37.73

Mets

ATPIII

11.1

(9.8–12.5)

ATPIII with waist> 90 cm

26.6

(24.7–28.5)

ATPIII> 95 cm

19.6

(17.9–21.3)

Sharma, 2016 [18],

India

C/S

Not provided

Military

aircrew

Convenience

210

20–50

Mets

MS-4

33.0

(26.6–39.7)

ATPIII

11.9

(7.6–16.7)

IDF

7.1

(4.0–11.7)

WHO

3.8

(1.8–7.6)

Gasier, 2016 [20],

US

C

Not provided

Navy

(Submariners)

Convenience

53

29

Mets

ATP-III

30.0

(18.7–44.5)

Baygi, 2016 [21],

Iran

C/S

2015

Seafarers

Convenience

234

36

Mets

IDF

14.9

(10.8–20.3)

Rhee, 2015 [23],

Korea

C/S

2014

Military aviators

Convenience

911

24–49

Mets

WHO

9.8

(7.9–11.9)

Herzog, 2015 [27],

US

C/S

2012

Military

Convenience

79,139

18–65

Mets

ATPIII

16.7

(15.7–16.2)

Filho, 2014 [9],

Brazil

C/S

2012

Military

Convenience

452

45.8

Mets

ATPIII

38.5

(34.0–43.2)

Scovill, 2012 [31],

US

C/S

Not provided

Mariner

Convenience

388

44

Mets

ATPIII

39.0

(34.1–43.9)

Hagnas, 2012 [33],

Finland

Prospectiv

Not provided

Military

Convenience

1046

19.2

Mets

IDF

6.1

(4.8–7.8)

Costa, 2011 [36],

Brazil

C/S

2008

Navy

Convenience

1383

30.7

Mets

IDF

17.6

(15.6–19.7)

Khazale, 2007 [43],

Jordan

C

2006

Air force

Convenience

111

32.5

Mets

ATPIII

18

(11.6–26.7)

Al-Qahtani, 2005 [47],

Saudi Arabia

C/S

2004

Soldiers

Convenience

1079

20–60

Mets

ATPIII

20.8

(18.4–23.3)

Athyros, 2005 [48],

Greece

C/S

2003

Military

Convenience

300

37.0

Mets

ATPIII

9.4

(6.4–13.3)

Bauduceau, 2005 [49],

France

C/S

2003

Military

Convenience

2045

38.6

Mets

ATPIII

WHO

9.0

(7.8–10.3)

14.0

(12.5–15.6)

  1. C/S: Cross-sectional; C: Cohort; Mets: Metabolic Syndrome; ATPIII: Adult Treatment Panel III; IDF: International Diabetes Federation; WHO: World Health Organization